DDInter1377 DDInter1676
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Paclitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Paclitaxel {u} (Compound) treats {v} (Disease) breast cancer
Paclitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Paclitaxel {u} (Compound) upregulates {v} (Gene) CDCA8
Paclitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Paclitaxel {u} (Compound) downregulates {v} (Gene) SCAND1
Paclitaxel {u} (Compound) causes {v} (Side Effect) Swelling face
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Paclitaxel (Compound) resembles Docetaxel (Compound)
Paclitaxel (Compound) treats breast cancer (Disease)
Paclitaxel (Compound) binds CYP3A5 (Gene)
Paclitaxel (Compound) upregulates CDCA8 (Gene)
Paclitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Paclitaxel (Compound) downregulates SCAND1 (Gene)
Paclitaxel (Compound) causes Swelling face (Side Effect)
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Delafloxacin